A Translational and Neurocomputational Evaluation of a D1R Partial Agonist for Schizophrenia

A Translational and Neurocomputational Evaluation of a D1R Partial Agonist for Schizophrenia
Recruiting
100 years or below
All
Phase N/A
1 Location

Brief description of study

The purpose of this research is to test an experimental drug CVL-562 as a possible treatment for early-course schizophrenia, schizoaffective disorder or related psychotic disorder.

This study will test whether CVL-562 can help thinking and memory in people with schizophrenia.

Detailed description of study

The study involves 7 in-person visits, including an initial intake visit, 5 scan visits, and 1 follow up visit, as well as a brief phone check in 1 month after completion of the study. An investigational medication is taken prior to the scan on each of the 5 scan visits. In addition to medical assessments, subjects will participate in clinical interviews, cognitive assessments, and MRIs. Total compensation is up to $2,910.

Visit our website: https://clinicaltrials.gov/ct2/show/NCT04457310?term=PF-06412562&cond=Schizophrenia&draw=2&rank=2

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: acne,related psychotic disorders
  • Age: 100 years or below
  • Gender: All

Inclusion Criteria:
Exclusion Criteria:

Updated on 19 Feb 2024. Study ID: TX842909

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.